After signing up, you'll start to receive regular news updates from us.
Genaissance Enters Pharmacogenomic Collaboration with Otsuka
Complete the form below to unlock access to ALL audio articles.
Genaissance Pharmaceuticals, Inc. has announced that it has entered into a pharmacogenomic research collaboration with Otsuka Pharmaceutical Co., Ltd.
Under the terms of the agreement, Genaissance will apply its HAP™ Technology with the goal of identifying genetic markers related to drug response.
Genaissance and Otsuka will be co-owners of the intellectual property that results from the collaboration and both companies will be eligible to receive royalties on revenues generated from diagnostic products resulting from the collaboration.
"We are very pleased that we will be collaborating with Otsuka," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals.
"We believe this agreement is another indication that pharmacogenomics is becoming an important tool for drug development."
